Hyperlipidemia
📧 Sign up to get email alerts when something new happens for Hyperlipidemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-06-14FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for atorvastatin calcium from NorthStar RxLLC, authorizing a generic version of atorvastatin.
-
FDA approval · 2024-06-11FDA Approved: PITAVASTATIN — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for pitavastatin from Aurobindo Pharma Limited.
-
FDA approval · 2024-06-10FDA Approved: EZETIMIBE AND SIMVASTATIN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's Supplemental Application for the fixed-dose combination ezetimibe and simvastatin (EZETIMIBE AND SIMVASTATIN).
-
CLINICAL_TRIALS research · 2024-06-06Clinical Trial Update: Chart Review of Repatha® in Subjects With Hyperlipidaemia
This is a completed chart-review study evaluating the use of Repatha (evolocumab) in subjects with hyperlipidemia and/or hypercholesterolemi…
-
FDA approval · 2024-06-03FDA Approved: EZETIMIBE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for ezetimibe filed by Glenmark Pharmaceuticals Inc., USA.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-06-03FDA Approved: EZETIMIBE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ezetimibe from Aurobindo Pharma Limited, confirming regulatory approval of this generic ezetimib…
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation
A completed clinical trial from NIDCD examined whether statin therapy influences hearing loss in patients with head and neck squamous cell c…
-
CLINICAL_TRIALS research · 2024-05-21Clinical Trial Update: Effect of Nigella Sativa in Atorvastatin Treated Hyperlipidaemia [Phase 2]
Phase 2 clinical trial evaluating the effect of Nigella sativa in patients with hyperlipidemia already treated with atorvastatin; recruitmen…
-
CLINICAL_TRIALS research · 2024-05-20Clinical Trial Update: Effect of a Customised Lifestyle Medicine Strategy on Lowering Blood Lipid Levels in Indian Physicians [NA]
This clinical trial update reports on a study evaluating a customized lifestyle medicine approach to lower lipid levels in Indian physicians…
-
FDA approval · 2024-05-17FDA Approved: GEMFIBROZIL — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for Gemfibrozil submitted by Chartwell RX, LLC.
-
FDA approval · 2024-05-17FDA Approved: AMLODIPINE AND ATORVASTATIN — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for the combination product amlodipine and atorvastatin from Prasco Laboratories, enabling its conti…
-
FDA approval · 2024-04-30FDA Approved: EZETIMIBE — Supplemental Application (Ohm Laboratories Inc.)
The FDA approved a supplemental application for ezetimibe from Ohm Laboratories Inc., updating the regulatory status of the product.
-
FDA approval · 2024-04-30FDA Approved: PITAVASTATIN CALCIUM — Original Application (NorthStar RxLLC)
FDA approved NorthStar RxLLC's original application for pitavastatin calcium, a generic statin, to treat hyperlipidemia by lowering choleste…
-
FDA approval · 2024-04-29FDA Approved: EZETIMIBE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved Macleods Pharmaceuticals Limited's original application for ezetimibe, a generic version of the cholesterol-lowering drug.
-
FDA approval · 2024-04-04FDA Approved: PITAVASTATIN — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved Teva's supplemental application for pitavastatin calcium (pitavastatin) under ANDA205932.
-
FDA approval · 2024-04-02FDA Approved: LIPITOR — Supplemental Application (Viatris Specialty LLC)
FDA has approved a supplemental application for Lipitor (atorvastatin calcium) submitted by Viatris Specialty LLC to update labeling.
-
FDA approval · 2024-03-29FDA Approved: EZETIMIBE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for ezetimibe filed by Quallent Pharmaceuticals Health LLC. This confirms approval of a new or m…
-
CLINICAL_TRIALS trial_result · 2024-03-25Clinical Trial Update: Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support [Phase 3]
Novartis completed a Phase 3 trial evaluating how inclisiran is delivered in primary care with enhanced support, focusing on implementation …
-
FDA approval · 2024-03-22FDA Approved: NEXLIZET — Supplemental Application (Esperion Therapeutics, Inc.)
The FDA approved a supplemental application for Nexlizet (bempedoic acid and ezetimibe) by Esperion Therapeutics.
-
FDA approval · 2024-03-20FDA Approved: EZALLOR SPRINKLE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for EZALLOR SPRINKLE (rosuvastatin) by Sun Pharmaceutical Industries, expanding its approved ros…
-
FDA approval · 2024-03-14FDA Approved: LIVALO — Supplemental Application (Kowa Pharmaceuticals America, Inc.)
FDA approved a supplemental application for LIVALO (pitavastatin calcium) submitted by Kowa Pharmaceuticals America, Inc.
-
FDA approval · 2024-03-12FDA Approved: ROSUVASTATIN — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA supplemental approval has been granted for rosuvastatin from Camber Pharmaceuticals, indicating an approved supplemental application for…
-
FDA approval · 2024-03-08FDA Approved: PRALUENT — Supplemental Application (Regeneron Pharmaceuticals, Inc.)
FDA approved Regeneron's supplemental application for PRALUENT (alirocumab), confirming expanded regulatory authorization.
-
CLINICAL_TRIALS trial_result · 2024-02-26Clinical Trial Update: Medication Adherence Clinical Decision Support [NA]
Completed clinical trial evaluating medication adherence decision support in hyperlipidemia and hypertension with results posted in 2024.
-
FDA approval · 2024-02-21FDA Approved: ZETIA — Supplemental Application (Organon LLC)
FDA approved a supplemental application for Zetia (ezetimibe) from Organon LLC.